Sarepta COO shares withheld for RSU taxes

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported routine share dispositions tied to tax withholding rather than open-market sales.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported routine share dispositions tied to tax withholding rather than open-market sales. On March 9, 2026, a total of 1,619 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations from vesting restricted stock units granted on March 7, 2022 and March 6, 2023. After these transactions, Estepan directly owned 203,080 shares of Sarepta common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 1,619 shares

Exercise Price or Tax Liability 2 txns

Insider Estepan Ian Michael

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,036	$16.95	$18K
Exercise Price or Tax Liability	Common Stock	583	$16.95	$10K

Holdings After Transaction: Common Stock — 203,080 shares (Direct)

Footnotes (2)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
2. F2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta (SRPT) COO Ian Michael Estepan report?

Ian Michael Estepan reported company share withholdings for taxes, not open-market sales. On March 9, 2026, 1,619 Sarepta common shares were withheld to satisfy tax obligations arising from vesting restricted stock units granted in 2022 and 2023.

How many Sarepta (SRPT) shares were withheld for Ian Michael Estepan’s taxes?

A total of 1,619 Sarepta Therapeutics shares were withheld to cover tax obligations. The withholdings occurred in two Form 4 transactions of 1,036 shares and 583 shares, each priced at $16.95 per share, related to vesting restricted stock units.

Does the Sarepta (SRPT) Form 4 show Ian Michael Estepan selling shares on the market?

The Form 4 does not show open-market sales by Ian Michael Estepan. Instead, it reports company share withholdings for tax liabilities associated with vesting restricted stock units, a common, non-discretionary mechanism for handling compensation-related taxes.

How many Sarepta (SRPT) shares does Ian Michael Estepan hold after the reported transactions?

Following the tax-withholding dispositions, Ian Michael Estepan directly holds 203,080 shares of Sarepta common stock. This post-transaction balance reflects his remaining equity position after 1,619 shares were withheld by the company to satisfy RSU-related tax obligations.

What awards triggered the tax-withholding share dispositions for Sarepta (SRPT) COO Estepan?

The withholdings stem from restricted stock units that vested from prior grants. Footnotes state the taxes related to RSUs granted on March 7, 2022 and March 6, 2023, with shares withheld by Sarepta to satisfy the associated tax obligations at vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 08:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F(1)		1,036	D	$16.95	203,663	D
Common Stock	03/09/2026		F(2)		583	D	$16.95	203,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.